Identification of novel extracellular signal-regulated kinase docking domain inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4586-4595

  Hancock, Chad N ^b   Macias, Alba ^a   Lee, Eun Kyoung ^a   Yu, Su Yeon ^a   MacKerell Jr , Alexander D ^a   Shapiro, Paul ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYELIN BASIC PROTEIN; S6 KINASE; TRANSCRIPTION FACTOR ELK 1;

ARTICLE; CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; COLONY FORMATION; COMPUTER AIDED DESIGN; COMPUTER MODEL; CONTROLLED STUDY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FLUORESCENCE SPECTROSCOPY; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR WEIGHT; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION;

BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DATABASES, FACTUAL; DNA-BINDING PROTEINS; DRUG DESIGN; ETS-DOMAIN PROTEIN ELK-1; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TRANSCRIPTION FACTORS;

EID: 22244490088     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0501174     Document Type: Article

References (46)

1. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Herman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22, 153-183.
2. Kyriakis, J. M.; Avruch, J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 1996, 18, 567-577.
3. Reuter, C. W.; Morgan, M. A.; Bergmann, L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000, 96, 1655-1669.
4. Duesbery, N. S.; Webb, C. P.; Vande Woude, G. F. MEK wars, a new front in the battle against cancer. Nat. Med. 1999, 5, 736-737.
5. Shapiro, P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit. Rev. Clin. Lab. Sci. 2002, 39, 285-330.
6. Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3, 459-465.
7. Lewis, T. S., Shapiro, P. S., Ahn, N. G. Signal tranduction through MAP Kinase Cascades. Adv. Cancer Res. 1998, 74, 49-139.
8. Zhang, J.; Zhang, F.; Ebert, D.; Cobb, M. H.; Goldsmith, E. J. Activity of the MAP kinase ERK2 is controlled by a flexible surface loop. Structure 1995, 3, 299-307.
9. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49, 4682-4689.
10. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P. A.; Wooster, R.; Stratton, M. R.; Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62, 6997-7000.
11. Songyang, Z.; Lu, K. P.; Kwon, Y. T.; Tsai, L. H.; Filhol, O.; Cochet, C.; Brickey, D. A.; Soderling, T. R.; Bartleson, C.; Graves, D. J.; DeMaggio, A. J.; Hoekstra, M. F.; Blenis, J.; Hunter, T.; Cantley, L. C. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol. Cell Biol. 1996, 16, 6486-6493.
12. Zuniga, A.; Torres, J.; Ubeda, J.; Pulido, R. Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. J. Biol. Chem. 1999, 274, 21900-21907.
13. Fantz, D. A.; Jacobs, D.; Glossip, D.; Kornfeld, K. Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues. J. Biol. Chem. 2001, 276, 27256-27265.
14. Zhang, J.; Zhou, B.; Zheng, C. F.; Zhang, Z. Y. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates. J. Biol. Chem. 2003, 278, 29901-29912.
15. Nichols, A.; Camps, M.; Gillieron, C.; Chabert, C.; Brunet, A.; Wilsbacher, J.; Cobb, M.; Pouyssegur, J.; Shaw, J. P.; Arkinstall, S. Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J. Biol. Chem. 2000, 275, 24613-24621.
16. Tanoue, T.; Adachi, M.; Moriguchi, T.; Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2000, 2, 110-116.
17. Bollag, G.; Freeman, S.; Lyons, J. F.; Post, L. E. Raf pathway inhibitors in oncology. Curr. Opin. Investig. Drugs 2003, 4, 1436-1441.
18. Boldt, S.; Kolch, W. Targeting MAPK signaling: Prometheus' fire or Pandora's box? Curr. Pharm. Des. 2004, 10, 1885-1905.
19. Sebolt-Leopold, J. S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Des. 2004, 10, 1907-1914.
20. Allen, L. F.; Sebolt-Leopold, J.; Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 2003, 30, 105-116.
21. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
22. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem., Int. Ed. 2002, 41, 2644-2676.
23. Markowitz, J.; Chen, I.; Gitti, R.; Baldisseri, D. M.; Pan, Y.; Udan, R.; Carrier, F.; MacKerell, A. D., Jr.; Weber, D. J. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J. Med. Chem. 2004, 47, 5085-5093.
24. Loughney, D. A., Murray, W. V., and Jolliffe, L. K. Application of Virtual Screening Tools to a Protein-Protein Interaction: Database Mining Studies on the Growth Hormone Receptor. Med. Chem. Res. 1999, 9, 579-591.
25. Zeng, J.; Nheu, T.; Zorzet, A.; Catimel, B.; Nice, E.; Maruta, H.; Burgess, A. W.; Treutlein, H. R. Design of inhibitors of Ras- -Raf interaction using a computational combinatorial algorithm. Protein Eng. 2001, 14, 39-45.
26. Huang, N.; Nagarsekar, A.; Xia, G.; Hayashi, J.; MacKerell, A. D., Jr. Identification of nonphosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. J. Med. Chem. 2004, 47, 3502-3511.
27. Zhang, F.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994, 367, 704-711.
28. Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
29. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur. J. Biochem. 1977, 80, 319-324.
30. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
31. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
32. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983, 221, 709-713.
33. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graphics 1988, 6, 13-27.
34. Tanoue, T.; Maeda, R.; Adachi, M.; Nishida, E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J. 2001, 20, 466-479.
35. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1984, 28, 849-857.
36. Pan, Y.; Huang, N.; Cho, S.; MacKerell, A. D., Jr. Consideration of molecular weight during compound selection in virtual target-based database screening. J. Chem. Inf. Comput. Sci. 2003, 43, 267-272.
37. Leach, A. R.; Kuntz, I. D. Conformational analysis of flexible ligands in macromolecular receptor sites. J. Comput. Chem. 1992, 13, 730-748.
38. Ewing, T. J. A.; Kuntz, I. D. Critical evaluation of search algorithms used in automated molecular docking. J. Comput. Chem. 1997, 18, 1175-1189.
39. Butina, D. Unsupervised database clustering on daylight's fingerprint and Tanimoto similarity: A fast and automated way to cluster small and large data sets. J. Chem. Inf. Comput. Sci. 1999, 39, 747-750.
40. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
41. Cha, H.; Lee, E. K.; Shapiro, P. Identification of a C-terminal Region That Regulates Mitogen-activated Protein Kinase Kinase-1 Cytoplasmic Localization and ERK Activation. J. Biol. Chem. 2001, 276, 48494-48501.
42. Dangi, S.; Cha, H.; Shapiro, P. Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cell Signal 2003, 15, 667-675.
43. Cha, H.; Hancock, C.; Dangi, S.; Maiguel, D.; Carrier, F.; Shapiro, P. Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross reactive phosphorylation specific MKK1/2 antibodies. Biochem. J. 2004, 378, 857-865.
44. Shapiro, P. S.; Whalen, A. M.; Tolwinski, N. S.; Wilsbacher, J.; Froelich-Ammon, S. J.; Garcia, M.; Osheroff, N.; Ahn, N. G. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol. Cell Biol. 1999, 19, 3551-3560.
45. Marshall, G. Biophysical Chemistry: Principles, Techniques, and Applications; John Wiley & Sons: New York, 1978.
46. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.